News from grünenthal group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 29, 2022, 06:56 ET Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis

Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's...

Mar 07, 2022, 07:25 ET Grünenthal donates 400.000€ and provides pain treatment medicine to Ukraine

Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000€ to the Red Cross to support humanitarian...

Jan 24, 2022, 04:46 ET EFIC® and Grünenthal Announced Winners of Pain Research Grant 2022

The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five recipients of the EFIC-Grünenthal Grant (E-G-G). ...

Sep 29, 2021, 05:53 ET First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist

Today, Grünenthal announced that the first participants have been enrolled in a randomised, placebo- and active-controlled clinical trial for its...

Aug 10, 2021, 03:00 ET First patient enrolled in a Phase III study with QUTENZA® in post-surgical neuropathic pain

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001....

Jul 27, 2021, 05:15 ET Grünenthal's Glucocorticoid Receptor Modulator enters clinical development

Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM). The oral...

Jul 20, 2021, 04:39 ET Flood disaster: Grünenthal donates 400,000 euros as emergency relief

Grünenthal is deeply saddened by the situation of the people affected by the flood disaster in Germany. Staff and executive management have set up a...

Jul 20, 2021, 04:37 ET Flood disaster: Grünenthal donates 400,000 euros as emergency relief

Grünenthal is deeply saddened by the situation of the people affected by the flood disaster in Germany. Staff and executive management have set up a...

May 04, 2021, 04:18 ET Grünenthal is one of the best employers in North Rhine-Westphalia

Grünenthal, an international pharmaceutical company headquartered in Aachen, announced today that it will be recognised as one of the best employers...

Apr 12, 2021, 08:00 ET Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee

Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech...

Mar 01, 2021, 07:12 ET Grünenthal Germany is a Great Place to Work®

Grünenthal Germany is now certified as a Great Place to Work® and a Great Start! company for apprentices. The company was awarded these two...

Feb 12, 2021, 07:37 ET Grünenthal successfully extends its term loan bank facilities

Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader ...

Feb 10, 2021, 02:00 ET Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin)

Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total...

Jan 12, 2021, 03:00 ET Florian Dieckmann new VP Global Communications at Grünenthal

Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štěpán Kráčala, who...

Dec 16, 2020, 05:28 ET Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development

Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide ...

Dec 01, 2020, 03:58 ET Grünenthal agrees to acquire European rights to CRESTOR™ (rosuvastatin) from AstraZeneca

Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights...

Jul 21, 2020, 11:38 ET Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA®...

Feb 04, 2020, 04:42 ET Grünenthal Invests in e-mobility at Headquarters in Aachen

Grünenthal, a global leader in pain management and related diseases, has announced it will now include electric and hybrid engines in the fleet of...

Jan 29, 2020, 06:41 ET Grünenthal Expands Its Network Through Innovation Hub in Boston

Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with...

Dec 18, 2019, 09:03 ET Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the Grünenthal Group, announced today that the supplemental New Drug...

Dec 10, 2019, 06:46 ET Jan Adams Appointed Chief Scientific Officer for Grünenthal

Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective ...

May 02, 2019, 08:52 ET Five Young Scientists Win EFIC-Grünenthal Grant 2018

The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as...

Jan 22, 2019, 05:25 ET Grünenthal: Fabian Raschke Appointed Chief Financial Officer (CFO)

Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will...

Dec 14, 2018, 02:00 ET Grünenthal and OnDosis Team Up for Individualised Dosing of Oral Drugs in Pain Management to Increase Patient Safety

Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription...

Nov 14, 2018, 03:27 ET Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to...